Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily
- PMID: 9152603
Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamily
Abstract
In vitro studies were conducted to identify the hepatic cytochrome P450 (CYP) protein(s) involved in the oxidative metabolism of [14C]clarithromycin (CLAR) in the presence of native human liver microsomes. The identity of the two major CLAR metabolites present in microsome incubates, 14-(R)-hydroxy-CLAR and N-desmethyl-CLAR, was confirmed by MS. Over the CLAR concentration range of 1.0-140 microM, the rate of CLAR 14-(R)-hydroxylation (KM = 48 +/- 17.7 microM; Vmax = 206 +/- 76 pmol/min/mg protein; Vmax/KM = 4.2 +/- 0.21 microliters/min/mg; mean +/- SD, N = 3 livers) and N-demethylation (KM = 59.1 +/- 24.0 microM; Vmax = 189 +/- 52.0 pmol/min/mg protein; Vmax/KM = 3.3 +/- 0.53 microliters/min/mg) conformed to monophasic (saturable) Michaelis-Menten kinetics and was highly correlated (r = 0.90-0.92; p < 0.001; N = 11) with CYP3A-selective erythromycin N-demethylase activity. Ketoconazole (< or = 2.0 microM) or troleadomycin, CYP3A-selective inhibitors, markedly decreased (> or = 99%) the formation of both metabolites, whereas inhibitors selective of other CYP forms were relatively ineffective (< or = 10% inhibition). In agreement with chemical inhibitor studies, CLAR metabolism was only detectable with human B-lymphoblastoid microsomes containing cDNA-expressed CYP3A4 (vs. CYP2C19, CYP2C9, CYP2D6, CYP1A2, CYP2E1, or CYP2A6). Furthermore, the apparent KM characterizing the 14-(R)-hydroxylation and N-demethylation of CLAR in the presence of insect cell microsomes containing cDNA-expressed CYP3A4 (KM = 18-63 microM) was similar to that obtained with native human liver microsomes. Based on the results of this study, it is concluded that the 14-(R)-hydroxylation and N-demethylation of CLAR is primarily mediated by one or more members of the human liver CYP3A subfamily.
Similar articles
-
Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.Drug Metab Dispos. 1996 Sep;24(9):940-7. Drug Metab Dispos. 1996. PMID: 8886602
-
Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.J Pharmacol Exp Ther. 2000 May;293(2):453-9. J Pharmacol Exp Ther. 2000. PMID: 10773015
-
Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.Drug Metab Dispos. 1996 Sep;24(9):948-54. Drug Metab Dispos. 1996. PMID: 8886603
-
Cytochrome P450 isozymes and antiepileptic drug interactions.Epilepsia. 1995;36 Suppl 5:S8-13. doi: 10.1111/j.1528-1157.1995.tb06007.x. Epilepsia. 1995. PMID: 8806399 Review.
-
Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes.Biochem Pharmacol. 1999 Mar 1;57(5):465-80. doi: 10.1016/s0006-2952(98)00268-8. Biochem Pharmacol. 1999. PMID: 9952310 Review.
Cited by
-
Acceleration of infectious disease drug discovery and development using a humanized model of drug metabolism.Proc Natl Acad Sci U S A. 2024 Feb 13;121(7):e2315069121. doi: 10.1073/pnas.2315069121. Epub 2024 Feb 5. Proc Natl Acad Sci U S A. 2024. PMID: 38315851 Free PMC article.
-
Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Br J Clin Pharmacol. 2014 Jan;77(1):141-8. doi: 10.1111/bcp.12177. Br J Clin Pharmacol. 2014. PMID: 23738582 Free PMC article. Clinical Trial.
-
Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1.Eur J Clin Pharmacol. 2013 Oct;69(10):1785-93. doi: 10.1007/s00228-013-1529-1. Epub 2013 Jun 9. Eur J Clin Pharmacol. 2013. PMID: 23748747 Clinical Trial.
-
Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.Dig Dis Sci. 2005 Mar;50(3):443-8. doi: 10.1007/s10620-005-2455-6. Dig Dis Sci. 2005. PMID: 15810623 Clinical Trial.
-
A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma.Exp Hematol Oncol. 2018 Aug 13;7:18. doi: 10.1186/s40164-018-0110-0. eCollection 2018. Exp Hematol Oncol. 2018. PMID: 30123673 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical